Jiangsu Hengrui Pharmaceuticals (SHA:600276, HKG:1276) said a unit received marketing approval from China's National Medical Products Administration for Cyclosporine Ophthalmic Solution (IV), marketed as CyclASol, according to a Thursday Hong Kong bourse filing.
CyclASol is indicated to promote tear secretion and improve the signs and symptoms of dry eye disease in patients with reduced tear production.